Gilead Sciences D
D
GILD
112.555
USD
-1.36
(-1.19%)
مغلق
حجم التداول
136,350
الربح لكل سهم
8
العائد الربحي
2.74
P/E
22
حجم السوق
139,659,022,430
الأخبار المقالات
العنوان: Gilead Sciences
القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis Cdrug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).